What is the Billion Cell Atlas and what is it building?

The Billion Cell Atlas is an alliance building the world's largest genome-wide genetic perturbation dataset by sequencing hundreds of millions of cells. It uses CRISPR to capture how individual cells respond to genetic changes across more than 200 disease-relevant cell lines, creating over six petabytes of functional genomics data.

How does this help Eli Lilly's drug discovery?

The dataset provides a large experimental dataset for AI-driven target discovery and drug design, helping Eli Lilly identify new drug targets and understand disease mechanisms. This can help broaden future drug targets beyond its current cardiometabolic disease focus into areas like neuroscience.

Which other companies are in this alliance?

The body names AstraZeneca and Merck as peers also positioned alongside Eli Lilly in the alliance, though Eli Lilly's specific role is as a foundational participant.

AI in HealthcareTop Companies' AI MovesAI Business & IndustryTop Companies AIJul 30, 2026Jul 31, 2026, 06:30 JST

Eli Lilly joins Illumina's Billion Cell Atlas for AI drug discovery

Send on LINE

3 Key Points

What happened
Eli Lilly has joined Illumina's Billion Cell Atlas alliance as a foundational participant. The alliance is sequencing hundreds of millions of cells to build what is described as the world's largest genome-wide genetic perturbation dataset, using CRISPR across more than 200 disease-relevant cell lines.
Why it matters
The dataset — over six petabytes of functional genomics data — gives Eli Lilly a tool to identify new drug targets and understand disease mechanisms in ways its current GLP-1 obesity and diabetes drugs do not cover. This positions the company to broaden its pipeline into specialty areas like neuroscience and cardiometabolic disease, alongside peers such as AstraZeneca and Merck.
What to watch
Investors should track how this collaboration translates into future pipeline breadth and the quality of new drug targets, especially in complex diseases. The company's narrative has focused heavily on GLP-1 volume and pricing, so the potential impact of large shared genomics platforms on long-term pipeline quality may not yet be fully reflected in the market.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, in your inbox every morning.

Get news like this every morning, free

Context & Analysis

Eli Lilly's entry into Illumina's Billion Cell Atlas represents a long-term capability move rather than a near-term earnings driver. The alliance is fundamentally about building shared infrastructure for AI-powered drug discovery — a dataset of over six petabytes spanning more than 200 disease-relevant cell lines. For Eli Lilly, which has seen its stock rise 60.3% over the past year and 383.3% over five years, this partnership offers a way to deepen its research beyond the GLP-1 obesity and diabetes franchise that currently dominates its narrative.

The company's current story leans heavily on GLP-1 volume and pricing dynamics in cardiometabolic disease. Access to functional genomics data at this scale can help identify targets and mechanisms in specialty areas like neuroscience that may not be as crowded or price-sensitive. This also aligns Eli Lilly with how peer companies like AstraZeneca and Merck are positioning themselves in the emerging infrastructure for genomics-driven drug discovery. However, the body notes that this potential impact on future pipeline quality may not yet be fully reflected in current market perception, which remains focused on near-term GLP-1 dynamics.

FAQ

What is the Billion Cell Atlas and what is it building?: The Billion Cell Atlas is an alliance building the world's largest genome-wide genetic perturbation dataset by sequencing hundreds of millions of cells. It uses CRISPR to capture how individual cells respond to genetic changes across more than 200 disease-relevant cell lines, creating over six petabytes of functional genomics data.
How does this help Eli Lilly's drug discovery?: The dataset provides a large experimental dataset for AI-driven target discovery and drug design, helping Eli Lilly identify new drug targets and understand disease mechanisms. This can help broaden future drug targets beyond its current cardiometabolic disease focus into areas like neuroscience.
Which other companies are in this alliance?: The body names AstraZeneca and Merck as peers also positioned alongside Eli Lilly in the alliance, though Eli Lilly's specific role is as a foundational participant.

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Get it free

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.